Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of
Go back to Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of| (NASDAQ: BNTC) | Delayed: 13.00 -0.63 (4.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.63 | 52 Week High | $5.64 | |||
| Open | $13.63 | 52 Week Low | $1.20 | |||
| Day High | $14.33 | P/E | N/A | |||
| Day Low | $12.87 | EPS | $0.00 | |||
| Volume | 181,881 | |||||
